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Abstract
In patients undergoing major orthopaedic surgery, 
pre-operative anaemia, peri-operative bleeding and 
a liberal transfusion policy are the main risk factors 
for requiring red blood cell transfusion (RBCT). 
The clinical and economic disadvantages of RBCT 
have led to the development and implementation 
of multidisciplinary, multimodal, individualised 
strategies,  collectively termed patient blood 
management, which aim to reduce RBCT and improve 
patients' clinical outcome and safety. Within a patient 
blood management programme, low pre-operative 
haemoglobin is one of the few modifiable risk factors 
for RBCT. However, a survey among Anaesthesia 
Departments in Spain revealed that, although pre-
operative assessment was performed in the vast 
majority of hospitals, optimisation of haemoglobin 
concentration was attempted in <40% of patients who 
may have benefitted from it, despite there being enough 
time prior to surgery. This indicates that haemoglobin 
optimisation takes planning and forethought to be 
implemented in an effective manner. This review, based 
on available clinical evidence and our experience, is 
intended to provide clinicians with a practical tool to 
optimise pre-operative haemoglobin levels, in order 
to minimise the risk of patients requiring RBCT. To 
this purpose, after reviewing the diagnostic value and 
limitations of available laboratory parameters, we 
developed an algorithm for the detection, classification 
and treatment of pre-operative anaemia, with a patient-
tailored approach that facilitates decision-making in 
the pre-operative assessment. We also reviewed the 
efficacy of the different pharmacological options 
for pre-operative and post-operative management 
of anaemia. We consider that such an institutional 
pathway for anaemia management could be a viable, 
cost-effective strategy that is beneficial to both patients 
and healthcare systems.
Keywords: anaemia, iron deficiency, intravenous 
iron, recombinant erythropoietin, orthopaedic 
surgery.
Introduction 
Major orthopaedic surgery, especially hip and knee 
arthroplasties, results in significant peri-operative 
bleeding, which often exceeds one third of patients' 
blood volume1. As a result, a significant proportion 
of these patients receive allogeneic red blood cell 
transfusions (RBCT) to treat acute post-operative 
anaemia, although this practice is widely variable2. At 
present, orthopaedic surgery departments are responsible 
for over 7% of all packed red blood cell requests to 
hospital blood banks3. Population ageing is resulting 
not only in an increase in primary arthroplasties but also 
more revision procedures, which entail greater blood 
losses and transfusion requirements4.
Pre-operative anaemia, peri-operative bleeding and 
a liberal transfusion policy are the main risk factors 
for requiring RBCT1. There is now scientific evidence 
that RBCT is associated with increased post-operative 
mortality and morbidity, particularly nosocomial 
infections5,6. The clinical and economic disadvantages 
of RBCT in this scenario have fuelled a paradigm shift 
in Transfusion Medicine towards the development 
and implementation of multidisciplinary, multimodal, 
individualised strategies, collectively termed patient 
blood management (PBM), which aim to reduce RBCT 
and improve clinical outcome and safety7-9. PBM has 
been endorsed by the World Health Assembly requesting 
the World Health Organization (WHO) to provide its 
member states with training and support on the safe, 
rational use of RBCT and transfusion alternatives10 .
Within a PBM programme, low pre-operative 
haemoglobin (Hb) concentration is one of the few 
modifiable risk factors for RBCT, but its optimisation 
takes planning and forethought to be implemented in 
an effective manner. From pre-operative assessment to 
post-operative care in post-anaesthesia recovery units, 
anaesthesiologists play a key role in the implementation 
of RBCT minimisation strategies11. In Spain, the 
anaesthesiologist performs a pre-operative evaluation 
of patients undergoing major surgery in more than 86% 
of hospitals, and 74% of patients scheduled for major 
orthopaedic surgery are assessed between 1 week and 
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2 months prior to surgery12. Thus, major orthopaedic 
surgery is one of the most appropriate clinical 
settings for the optimisation of pre-operative Hb, as 
recommended in the Network of Advancement of Patient 
Blood Management, Thrombosis and Haemostasis 
(NATA) guidelines for the detection, assessment, and 
management of pre-operative anaemia13.
Mul t id isc ip l inary  col laborat ion between 
surgeons, anaesthesiologists, immunohaematologists, 
physiotherapists and nurses has allowed the 
implementation of PBM programmes for total 
arthroplasty of the hip or knee, which have resulted in 
a shorter time spent in hospital and a reduction in the 
all-cause readmission rate9,14. 
The aim of this review is to provide a practical 
tool to help clinicians optimise pre-operative Hb, 
according to the available clinical evidence and our 
experience, in order to minimise the risk of receiving 
RBCT15. For this purpose, we have developed a 
diagnostic and management algorithm (Figure 1), 
which should facilitate decision-making in the pre-
operative assessment, with an approach tailored to 
the patient who is willing to participate in medical 
decisions, knowing the risks and benefits of RBCT 
and its alternatives.
Implementation of patient blood management 
in Spain: the results of a survey in Anaesthesia 
Departments
Members from the Haemostasis and Transfusion 
Medicine section of the Spanish Society of 
Anaesthesiology and Reanimation (SEDAR) proposed 
conducting a survey among the heads or PBM key leaders 
of Anaesthesia Departments (n=91) in order to assess the 
actual implementation of PBM programmes throughout 
Spain. The survey consisted of 42 questions related to 
the characteristics of the pre-operative assessment, the 
existence of RBCT protocols and the use of alternatives 
to RBCT in different surgical scenarios, and the main 
factors limiting the implementation of PBM12.
According to the results yielded by this survey, the 
time frame between evaluation and surgery is generally 
long enough (30 days in >75% of patients) to implement 
an appropriate programme to optimise pre-operative Hb. 
Figure 1 - Consensus algorithm for pre-operative haemoglobin optimisation from the Spanish Best Practice in Peri-operative 
Anaemia Optimisation Panel from SEDAR (Sociedad Española de Anestesiología y reanimación)30* .
 1 If time available for Hb optimisation prior to surgery is short, there is intolerance to oral iron, functional iron deficiency 
or a poor response to rHuEPO, IV iron should be administered. 2 rHuEPO administration may be an off-label use for some 
operations, thus requiring a careful risk to benefit evaluation. 
 Explanatory notes: *the reduction of 1 g/dL in Hb concentration is equivalent to 150 mg iron loss. Thus, considering that 
1 ng/mL ferritin is equivalent to 8 mg of stored iron, for an expected Hb decrease of 3-4 g/dL a minimum of 60 ng/mL 
ferritin is needed to recover from post-operative anaemia.
 Hb: haemoglobin; CRP: C-reactive protein; GFR: glomerular filtration rate; IV: intravenous; rHuEPO: recombinant human 
erythropoietin. 
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Perioperative anaemia treatment in orthopaedic surgery
However, there is wide variability in local strategies 
for pre-operative management of anaemia among 
institutions. There is also great variability in transfusion 
criteria between the different hospitals surveyed. The 
lack of awareness of the risks associated with anaemia 
and RBCT among the healthcare staff, which creates 
barriers to a wider implementation of a comprehensive 
programme of appropriate RBCT use and treatment of 
pre-operative anaemia, could be behind the observed 
variability. 
Responders identified the need for a well-established 
pre-operative pathway, since the lack of involvement 
or collaboration of the surgical team is the main factor 
limiting optimal implementation of a PBM programme. 
Responders further identified lack of support from health 
authorities and hospital administrators, who should 
facilitate organisation, as a barrier to the implementation 
of multidisciplinary, multimodal PBM programmes, 
while cost issues were considered of lesser relevance.
From our point of view, it would be desirable for health 
organisations and/or public health services to be aware of 
the current use of RBCT and its alternatives. This, along 
with greater knowledge by healthcare professionals of 
the risks and costs of unnecessary or avoidable RBCT 
could contribute to greater use of PBM programmes16, 
with a particular focus on the treatment of pre-operative 
anaemia, as the first step in avoiding RBCT.
Anaemia in orthopaedic surgery: epidemiology 
Pre-operative anaemia is an important independent 
risk factor for RBCT in operations associated with 
moderate-to-severe blood loss, such as major orthopaedic 
surgery17-19. The prevalence of pre-operative anaemia in 
this population varies according to the type of surgery, 
age, gender and comorbidities present, but also depends 
on the criteria used to define anaemia20,21. The prevalence 
in the majority of series of patients undergoing elective 
major orthopaedic surgery ranged from 15 to 40%20-22. 
Up to 10% of women presented with a pre-operative Hb 
value between 12 and 13 g/dL18, which is considered 
normal according to WHO definitions. However, these 
Hb levels should be considered inappropriate for a 
major surgical procedure in which significant blood loss 
is anticipated17,19,23. In addition, up to 90% of patients 
undergoing these procedures develop post-operative 
anaemia24, which may be aggravated by inflammation-
induced blunted erythropoiesis25.
Almost one-third of anaemic orthopaedic patients 
have haematinic-deficiency anaemia, with iron 
deficiency being the most commonly observed form21,22, 
approximately one-third have anaemia of chronic 
inflammation22,26,27 (with or without chronic kidney 
disease), and just over one-third have anaemia of mixed 
cause or unexplained origin (Figure 2). 
The prevalence of anaemia of unexplained origin 
is relatively high among the elderly population28, as 
is that of major orthopaedic surgery. This anaemia is 
possibly caused by changes in stem cell physiology, 
including occult myelodysplasia, in some cases. The 
impact of changes in oestrogen or testosterone levels 
with age, multiple drug usage and a variety of medical 
conditions not classically associated with inflammation 
(e.g. hypothyroidism), could be other mechanisms. 
Treatment with erythropoietin has produced very good 
responses in this type of anaemia29. 
Pre-operative management of anaemia: the 
algorithm30 
According to NATA guidelines, all patients scheduled 
for major orthopaedic surgery should have their Hb and 
iron status tested at least 1 month prior to surgery in 
order to detect anaemia and haematinic deficiencies (a 
GRADE 1C recommendation, according to the Grades 
of Recommendation Assessment, Development and 
Evaluation classification). The second recommendation 
is that anaemia should always be corrected before 
elective surgery (GRADE 2C)13. This could entail 
rescheduling a major surgical procedure, when possible.
Anaemia management pathway
The main objective of a pre-operative assessment is 
to evaluate a patient's risks and optimise his or her health 
status in order to minimise the risks or improve safety. 
The assessment of RBCT risk within a PBM programme 
leads to a personalised plan to reduce or avoid exposure 
to RBCT and improve post-operative outcome. This is 
clearly a fundamental task of the anaesthesiologist11.
The pre-operative assessment is, therefore, the 
best moment to decide the most appropriate strategy 
to minimise the risk of RBCT, based on the type of 
intervention, the patient's health status, estimated time to 
surgery, and available blood-saving techniques31. Ideally, 
an institutional protocol agreed upon by surgeons, 
Figure 2 - Distribution of the main causes of pre-operative 
anaemia in patients scheduled for major orthopaedic 
surgery (modified from Bisbe et al.66). 
 ACD: anaemia of chronic disease.
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anaesthesiologists and haematologists in the Transfusion 
Committee should be followed. Such a protocol should 
also reduce healthcare costs (fewer patient evaluations) 
and optimise inclusion in the PBM programme.
The first step in the pre-anaesthetic assessment is 
the evaluation of risk factors for transfusion (Table I)
Of these factors, a low Hb level is one of the few 
that can be improved during the pre-operative period. 
The target Hb value to achieve (generally ≥13 g/dL) 
will depend on the type of intervention and the patient's 
characteristics23. The remaining factors will allow an 
estimation of transfusion risk in more than 80% of cases, 
facilitating the planning of complementary strategies.
The second step is to classify and treat pre-operative 
anaemia and hematinic deficiencies according to a very 
simple algorithm (Figure 3).
Our goal is optimise the pre-operative Hb level (as 
the most cost-effective strategy to minimise the exposure 
of surgical patients to the potential adverse effects of 
anaemia, RBCT or both) without compromising the 
patients' safety. Therefore, if major orthopaedic surgery 
is elective and the anaemia significant (Hb<10 g/dL) or 
unexpected, the procedure must be rescheduled and the 
patient referred to the appropriate specialist for evaluation 
and treatment of the anaemia. Should the anaemia 
be of known cause or less severe (Hb≥10 g/dL), the 
anaesthesiologist/nurse could proceed to its treatment. 
To this end, a pre-operative laboratory assessment should 
include a full blood count as well as an evaluation of 
iron status (e.g., ferritin) and markers of inflammation 
(e.g. C-reactive protein), to enable classification of 
the anaemia and appropriate pharmacological therapy, 
thus avoiding additional assessments. Alternatively, in 
some hospitals the laboratory screening is expanded 
automatically to cover a basic study of anaemia when the 
pre-operative analysis shows a Hb <12 g/dL in women or 
<13 g/dL in men. This latter approach will not, however, 
detect haematinic deficiency without anaemia.
There are a number of questions regarding a patient's 
erythropoiesis which need to be addressed before deciding 
how manage the anaemia (Table II). For example, could 
the patient be treated by the anaesthesiologist or should 
he or she be sent to a specialist? What is the target Hb 
level to achieve to minimise transfusion risk according 
to the patient's comorbid conditions, type of surgery, and 
characteristics? Can this Hb target be attained within a 
short time (<1 month) or should surgery be postponed? 
Diagnostic parameters 
A pre-operative assessment of iron status is 
recommended in patients undergoing major orthopaedic 
Table I - Risk factors for receiving perioperative blood 
transfusion.
- Surgeon's skill and experience. 
- Type of surgery: revision arthroplasty, scoliosis. 
- Female gender. 
- Low body mass. 
- Low pre-operative Hb level. 
- Haemostatic derangements (congenital and acquired defects).
- Drugs that alter haemostasis, such as antiplatelet agents, 
antidepressants, etc. 
- Co-morbidity, particularly cardiovascular or respiratory 
dysfunction.
Figure 3 - Pre-operative pathway for patient blood management.
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Perioperative anaemia treatment in orthopaedic surgery
surgery, as it can provide the correct indications for 
iron supplementation and predict the responsiveness 
to recombinant human erythropoietin (rHuEPO) 
administration32. The assessment of pre-operative iron 
status in Europe is not uniform: it is usual in Austria, 
Spain and Switzerland, unusual in France and the United 
Kingdom, and restrictively used in the Netherlands and 
Germany, where it is performed only if extremely low 
Hb values are found8. However, according to the NATA 
guidelines, pre-operative assessment of iron status 
should be considered the standard of care for anaemic 
patients undergoing major orthopaedic surgery13. 
Australian guidelines for the evaluation of pre-operative 
anaemia include determination of ferritin level and 
transferrin saturation, as well as an assay of C-reactive 
protein as a marker of inflammation.
It is important to include some iron parameters in the 
assessment of pre-operative anaemia. Decreased iron 
availability is the main factor limiting erythropoiesis 
and may be present in iron-deficiency anaemia after iron 
deposits have been exhausted and in anaemia of chronic 
disease, due to inflammation-induced iron sequestration. 
Functional iron deficiency is also the main cause of an 
inappropriate response to rHuEPO treatment33.
Biochemical parameters
Measurement of serum or plasma ferritin provides 
the most useful indirect estimate of body iron stores 
(1 ng/mL of serum ferritin corresponds to approximately 
8 mg of stored iron). It is universally available and well 
standardised, and the test of choice for detecting both iron 
deficiency and iron overload. Ferritin levels <30 ng/mL in 
anaemic patients are highly suggestive of iron-deficiency 
anaemia. As ferritin is a positive acute phase reactant, in 
patients of advanced age and those with inflammation 
or infection ferritin levels up to 60-100 ng/mL are also 
compatible with iron deficiency34.
As transferrin is the only iron-binding protein 
involved in iron transport, the transferrin saturation 
index (%TSAT) reflects the iron transport compartment. 
Its measurement is universally available and well 
standardised, although its value is influenced by 
daily and circadian variability of serum iron levels 
and transferrin (negative acute phase protein). The 
transferrin saturation index may be reduced (<20%) 
in both iron-deficiency anaemia, due to absolute iron 
deficiency with increased transferrin concentrations, and 
anaemia of chronic disease, due to iron sequestration in 
the reticuloendothelial system with normal or decreased 
transferrin levels. 
The levels of soluble transferrin receptor (sTfR) 
reflect the degree of iron availability to bone marrow cells. 
Upon depletion of functional iron, sTfR concentrations 
increase progressively while Hb concentration begins 
to fall. Circulating levels of sTfR are hardly influenced 
by inflammation or chronic disease, allowing the 
diagnosis of iron deficiency in patients of advanced 
age who have normal ferritin values27. However, sTfR 
levels also reflect increased erythropoietic activity 
(haemolytic anaemia, chronic lymphocytic leukaemia, 
therapy with rHuEPO). The ferritin index (sTfR/log 
ferritin) has a better discriminatory capacity than ferritin 
or sTfR separately. However, measurement of sTfR is 
expensive, not universally available, and the method is 
not standardised, further limiting a wider utilisation of 
this parameter.
Red cell variables
A routine complete blood count yields red cell 
indices, such as mean corpuscular volume, mean 
corpuscular Hb and red cell distribution width, which 
are useful for classifying simple cases of anaemia. These 
indices are also useful in assessing trends over periods 
of weeks or months, but have no use in assessing acute 
changes in iron availability. 
There are, however, important haematological 
indices, such as the reticulocyte Hb content (CHr) and 
percentage of hypochromic red blood cells (%Hypo), 
which may help in the diagnosis of functional iron 
deficiency, although they can only be measured 
by specific haematology analysers. %Hypo is the 
best-established parameter for the identification of 
functional iron deficiency and seems to be superior to 
measurements of sTfR35. %Hypo values are related to 
iron status in the preceding 2-3 months36, because of 
the long circulating life-span of mature erythrocytes. 
CHr is the next most established option but this test 
provides an early direct measurement of iron supply to 
red blood cell production (<7 days). Both haematological 
indices are direct indicators of functional iron deficiency 
in contrast to the majority of biochemical markers35. 
These parameters are also good predictors of response 
to intravenous (IV) iron administration37. 
The reticulocyte count is an important adjunct to CHr 
for evaluating response to treatment. While reticulocytes 
Table II - Relevant questions for managing preoperative 
anaemia.
- Is the patient's Hb adequate for the proposed surgery? 
- Are there sufficient deposits of haematinic nutrients? 
- Is anaemia an expected finding in this patient? 
- Does the severity of anaemia require immediate intervention? 
- Should surgery be postponed until the evaluation and treatment 
of anaemia are completed? 
- Is there any co-morbidity that may affect oxygen transport? 
- Can the apparent cause of anaemia be deduced from laboratory 
parameters and/or the patient's medical history?
Hb: haemoglobin.
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indicate the adequacy of red blood cell production in 
response to erythropoietin, the CHr level indicates 
actual red blood cell Hb content. If iron stores are low, 
any reticulocytes produced may have a low Hb content. 
Treatment of pre-operative anaemia and 
hematinic deficiencies 
The purpose of pharmacological treatment of pre-
operative anaemia is to achieve, at least, normal Hb 
values, as defined by the WHO13. However, in the 
context of major orthopaedic surgery, the target Hb to 
minimise the risk of requiring a transfusion should be 
customised according to the type of surgery and the 
patient's characteristics. Thus, for women scheduled for 
hip or knee arthroplasty, it would be desirable to achieve 
a Hb value ≥13 g/dL to minimise the risk of transfusion23, 
whereas for revision of total hip arthroplasty the Hb 
target may be ≥14 g/dL, since peri-operative bleeding 
usually exceeds 30% of the patient's blood volume4.
In one-third of anaemic patients undergoing major 
orthopaedic surgery, the anaemia may be effectively 
corrected before surgery by pharmacological treatment 
such as iron, folic acid, and vitamin B12. In iron-
deficiency anaemia, choice regarding which iron 
preparation to administer and by what route are not 
simple. Oral administration of iron may be the route 
of choice for anaemic patients whose surgery is not 
urgent, due to its low cost and simplicity. However, 
elderly patients taking multiple drugs (e.g. proton pump 
inhibitors) are often intolerant of, or unresponsive 
to, oral iron. In addition, the time required to correct 
anaemia and replenish iron stores make the oral route 
unhelpful for most patients.
If the time before surgery is short or the patient 
does not tolerate oral iron or has a poor response to 
it, IV iron supplementation is indicated as a safe and 
effective alternative for the treatment of pre-operative 
anaemia: it has fewer side effects and adherence to 
this treatment is better than that for oral iron38,39. IV 
supplementation is the route of choice in functional 
iron deficiency. Should the response to IV iron not be 
optimal in 2-3 weeks, a dose of subcutaneous rHuEPO 
may be administered. 
Most IV iron formulations available in Europe 
(Table III) are safe and effective at correcting absolute 
or functional iron deficiency in anaemic patients 
undergoing major orthopaedic surgery, and produce an 
average Hb increase of 1 to 3 g/dL in 1 month40,41. It is 
important to stress that administration of IV iron alone 
never results in supra-physiological Hb levels and will 
not, therefore, increase the risk of thromboembolic 
complications.
Newer IV iron formulations, such as ferric 
carboxymaltose, low molecular weight iron dextran 
or iron isomaltoside-1000, are more robust and stable, 
allow rapid administration of up to 1,000 mg in a single 
dose, and result in prompt, effective pre-operative iron 
replacement. These newer IV iron formulations may, 
therefore, facilitate treatment and be more convenient 
both for the patient (fewer venepunctures, less time 
off work) and for the healthcare system (shorter 
administration time, fewer day-hospital assessments and 
fewer ambulance transfers, which may offset their higher 
acquisition cost)40. Finally, it should be emphasised that 
iron deficiency without anaemia also needs correction, 
since it may compromise both the optimisation of pre-
operative Hb levels and the recovery from post-operative 
anaemia secondary to haemorrhage.
Elderly patients with anaemia of unknown cause, 
kidney disease or mild myelodysplastic syndrome show 
a good response to rHuEPO administration, although 
adequate iron supply should always be ensured, preferably 
via the IV route42. The dose of IV iron should be calculated 
according to the desired increase in Hb, without regard 
to replenishment of iron stores. For example, if an 80-
year old patient scheduled for total knee arthroplasty 
with a Hb of 11 g/dL, ferritin of 150 ng/mL and no 
comorbidity or contraindication to treatment were to be 
prescribed two doses of rHuEPO (2×40,000 IU) in order 
to raise the Hb level to 13 g/dL (a 2 g/dL increment), 
Table III - Some characteristics of IV iron formulations.
Carbohydrate shell Carboxymaltose Sucrose Isomaltoside-1000 Low molecular 
weight dextran
Sodium ferric 
gluconate
Complex type Type I
Robust and strong
Type II
Semi-robust and strong
Type I
Robust and strong
Type I
Robust and strong
Type III
Labile and weak
Maximal single dose 1,000 mg 200 mg 20 mg/kg 20 mg/kg 125 mg
Administration time 15 min 30 min >15 min (up to 1,000 mg) 
≥30 min (>1,000 mg)
4-6 h 1 h
Maximal weekly dose 1,000 mg 600 mg  20 mg/kg 20 mg/kg 125 mg
Presentation
   Vial volume 2,10 and 20 mL 5 mL 1,5 and 10 mL 2 mL 5 mL
   Concentration 50 mg/mL 20 mg/mL 100 mg/mL 50 mg/mL 12.5 mg/mL
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co-administration of 500 mg IV would be sufficient to 
meet iron requirements for erythropoiesis. 
In a recent study43, patients scheduled for knee 
or hip arthroplasty who had a Hb<13 g/dL, without 
classification of the type of anaemia, were initially 
treated with one dose of IV iron (1,000 mg) and 
subcutaneous rHuEPO (40,000 IU) if there were no 
contraindications. They also received pre-operative 
supplementation with parenteral vitamin B12 (1 mg) 
and oral folic acid (5 mg/day) to treat or prevent any 
functional or absolute deficiencies. After 14 days, 
patients who were still anaemic (15%) received a second 
dose of IV iron, rHuEPO and vitamin B12. All treated 
patients presented with normal Hb levels (≥13 g/dL) 
on the day of surgery, resulting in a reduction of RBCT 
rate. Although we believe that treatment should be 
targeted to the type of anaemia, this pragmatic approach 
achieved the goal of correcting pre-operative anaemia 
and reducing RBCT in a very simple way and with few 
adverse effects44.
In contrast, a recent randomised controlled trial 
showed that administration of four doses of rHuEPO 
plus oral iron, starting 3 weeks prior to the scheduled 
procedure, significantly decreased RBCT rates in 
anaemic patients (Hb<13 g/dL) undergoing lower 
limb arthroplasty, but not the number of transfused 
units and at an unacceptably high cost (€ 7,300 per 
avoided transfusion) and with a trend to a higher rate 
of cardiovascular adverse events45. Thus, routine, 
uncontrolled use of four doses of rHuEPO in patients 
undergoing major orthopaedic surgery should be 
seriously questioned.
Treatment of post-operative anaemia 
Post-operative anaemia after major orthopaedic 
surgery is primarily caused by peri-operative 
bleeding, although it is exacerbated or maintained 
by the inflammatory response to surgical injuries25. 
A common treatment of acute, severe post-operative 
anaemia is RBCT, administered in order to avoid 
tissue hypoxia-related morbidity and mortality. 
Available evidence shows that a restrictive transfusion 
threshold (Hb 7-8 g/dL) does not increase morbidity or 
mortality, even in elderly patients with cardiovascular 
risk46-48. Application of restrictive transfusion triggers 
has resulted in many patients being discharged with 
significant post-operative anaemia which may be 
accompanied by iron deficiency. Both anaemia and iron 
deficiency could hamper early rehabilitation and return 
to daily activities49.
Thus, as part of the first pillar of PBM, treatment of 
post-operative anaemia is aimed at avoiding RBCT and 
improving post-operative outcome7, physical performance 
and quality of life50, and should not be neglected.
Peri-operative bleeding implies considerable iron 
loss (150-200 mg of iron for each gram of Hb decrease). 
Moreover, as Van Iperen et al. demonstrated, surgical 
injuries induce a state of hypoferraemia in the presence 
of adequate iron stores, due to inflammation25. The 
degree of this transient form of functional iron deficiency 
is related to the extent of the surgery. This could explain 
why post-operative oral iron is not useful for accelerating 
the recovery from anaemia or reducing the RBCT 
rate following major surgical procedures and is not, 
therefore, recommended51 (GRADE 1B). In contrast, 
IV iron could play an important role in this context15. 
However, published studies on the efficacy of post-
operative IV iron are scant and mostly observational, 
retrospective, and focused on the reduction of RBCT 
rate52,53, rather than on the improvement of anaemia and 
its effects on physical performance and quality of life. 
It should also be noted that IV iron was administered 
peri-operatively in most studies (some doses of 
iron were administered just before surgery) and not 
selectively targeted to anaemic patients. In addition, 
some patients with Hb<13 g/dL received a single dose 
of rHuEPO53. However, in a prospective randomised 
study of 200 patients with hip fracture, Serrano-Trenas 
et al. highlighted that peri-operative monotherapy with 
IV iron resulted in a significant reduction of RBCT 
only among patients presenting with a Hb>12 g/dL or 
subcapital fracture, and did not influence post-operative 
morbidity54. Based on the evidence supplied by these 
studies, the Seville Consensus Document suggests short-
term peri-operative treatment with IV iron in anaemic 
patients subjected to major orthopaedic surgery in order 
to reduce the RBCT rate (GRADE 2B)15. Similarly, 
United Kingdom guidelines for the management of 
pre-operative anaemia recommend that, when surgery is 
urgent, whatever time is available before the operation 
should still be used to investigate anaemia and initiate 
treatment (GRADE 1C)55. 
One of the first studies on the effectiveness of IV 
iron for the treatment of post-operative anaemia was 
conducted in a small sample of children with moderate-
to-severe anaemia after spinal surgery (Hb<9 g/dL); 
the Hb increased 0.36 g/dL per day in patients given 
IV iron compared to 0.25 g/dL per day in those treated 
with oral iron56. In a more recent study of adult patients 
undergoing major orthopaedic surgery, post-operative 
administration of 600 mg IV iron to anaemic patients 
(Hb<10 g/dL) reduced the RBCT rate from 84 to 46%; 
however, the study was retrospective and included 
patients who underwent total hip arthroplasty for hip 
fracture repair52.
In a recently published clinical trial50, patients who 
underwent total knee arthroplasty and had a Hb<12 g/dL the 
day after surgery were given oral iron for 30 days or a single 
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dose of ferric carboxymaltose IV (825±125 mg). Compared 
to oral iron, IV iron resulted in higher rates of correction 
of anaemia (42 vs 23%) and iron deficiency (87 vs 35%) 
on day 30 after surgery. The primary outcome variable 
of this study was not RBCT, as Hb was optimised before 
surgery in all anaemic patients and the expected RBCT 
rate was very low (5%). However, differences in Hb 
level and some quality of life scores on post-operative 
day 30 were significant only for patients with low 
pre-operative iron stores and/or moderate-to-severe 
pre-operative anaemia. Similar results were observed 
for patients with low iron stores (ferritin <100 ng/mL) 
who received 400 mg iron sucrose 1-2 days before 
total knee arthroplasty57. In contrast, Karkouti et al.58 
observed that post-operative IV iron administration, 
either alone or in combination with rHuEPO, did not 
affect Hb concentrations during the first week after 
surgery, thus scarcely the influencing RBCT rate. Once 
again, the study sample was too small (10 patients per 
group) to make firm conclusions and patients underwent 
different types of surgery (major orthopaedic surgery 
and on-pump cardiac surgery). 
Treatment of pre-operative anaemia from an 
economic perspective
Current economic constrictions are challenging the 
sustainability of the public healthcare system. Therefore, 
in addition to issues concerning patients' safety, the 
cost-benefit balance of any therapeutic intervention is 
of paramount importance. In this regard, rational use 
of RBCT16 and its alternatives, such as optimisation of 
pre-operative Hb, may offer significant cost savings to 
the healthcare system, despite an initially perceived cost 
increment due to acquisition of drugs and devices59.
Enko et al.26 compared pre-operative anaemia 
treatment implemented according to an algorithm vs 
conventional practice in patients undergoing major 
orthopaedic surgery. The overall therapeutic costs of 
the group that received preoperative IV iron and/or 
rHuEPO were cost-neutral compared with those for the 
untreated group (€ 35.7 and € 36, respectively) because 
of less RBCT use in the former group. 
A correct economic assessment should also take into 
account "transfusion costs", which may be three to four 
times higher than the "acquisition costs"60, as well as 
costs derived from RBCT-associated early and delayed 
reactions and adverse events.
When comparing the costs of blood-saving 
strategies, such as treatment of pre-operative anaemia, 
with those of RBCT, a number of issues should be 
considered. These include not only the costs of adverse 
effects for which a causal relationship can be established 
(e.g. wrong blood episodes, transmission of infectious 
diseases, transfusion-related acute lung injury), but 
also those derived from the worse outcomes of patients 
receiving RBCT (e.g. increased rates of nosocomial 
infections, kidney failure, thromboembolic events, 
prolonged mechanical ventilation), which lead to longer 
stays in hospital and higher readmission rates61. Using 
the American College of Medical Quality database, 
Morton et al. quantified a $ 17,000 increment in health 
spending for each transfused patient62.
In the context of major orthopaedic surgery (knee 
and hip arthroplasties), treatment of pre-operative 
anaemia with a comprehensive PBM programme results 
in significant economic savings, despite the increment 
in direct costs for pharmaceuticals and reinfusion drain 
devices. In a study by Kotze et al.9, the application of 
PBM in 281 patients undergoing major orthopaedic 
surgery was estimated to have saved € 160,000, since 
reduction of RBCT-associated morbidity shortened the 
time spent in hospital by 0.7 days and decreased the 
readmission rate by 5%.
It should be noted that even the particular IV iron 
formulation used to treat pre-operative anaemia can 
affect the cost-benefit balance. In major orthopaedic 
surgery, the administration of 1,000 mg ferric 
carboxymaltose, instead of iron sucrose, resulted in 
€ 63 savings per patient, despite the drug acquisition 
cost for the former being more than € 100 higher40. 
The full dosage of ferric carboxymaltose can be 
administered in one session, instead of the five 
required to give iron sucrose, and with a shorter 
infusion time (15 min/infusion vs 30 min/infusion, 
respectively) (Table III). This saving only took into 
account the decrease in administration costs (day 
hospital, infusion drip, saline, nursing time, etc.), but 
savings in travel expenses and loss of work should 
also be added. Similarly, using a cost-minimisation 
analysis, Calvet et al.63 found that pre-operative 
ferric carboxymaltose infusion was less costly than 
iron sucrose infusion or oral iron replacement and 
appeared to reduce the total costs in patients with 
iron-deficient anaemia and colon cancer.
Muñoz et al. published a cost-analysis study on 
post-operative treatment with two IV iron preparations 
following total knee or hip arthroplasty. The results 
showed that IV treatments were effective at reducing the 
percentage of patients receiving allogeneic transfusions 
and the number of transfused units and were cost-neutral 
in the different cost scenarios evaluated64.
In a more comprehensive manner, the Government 
of Ontario quantified that implementation of PBM 
programmes for four surgical procedures (cardiac 
surgery, radical prostatectomy, knee and hip arthroplasty) 
resulted in $ 10.5 million savings in packed red cells and 
$ 39 million savings in health care, whereas the costs 
of implementing PBM were $ 3 million65.
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Key messages
- Pre-operative anaemia is frequent among patients 
undergoing major orthopaedic surgery and is, in 
itself, a risk factor for poor clinical outcome.
- Pre-operative anaemia is also one of the strongest 
predisposing factors for peri-operative transfusion, 
which in turn increases post-operative morbidity, 
mortality and costs. 
- Patients undergoing major orthopaedic surgery should 
have a complete blood cell count, and assessment of 
iron status and a markers of inflammation, preferably 
30 days before the scheduled procedure.
- Unexpected or severe pre-operative anaemia should 
be considered an indication for rescheduling any 
elective major orthopaedic surgery until evaluation 
and treatment are completed, when possible.
- Patients undergoing major orthopaedic surgery with 
pre-operative iron deficiency anaemia may benefit 
from oral iron therapy provided that it is tolerated, 
that there are no contraindications, and that there is 
sufficient time prior to surgery.
- IV iron supplementation should be considered if 
there is poor absorption or poor tolerance of oral 
iron, ongoing blood loss or an accelerated response 
to treatment is required. 
- When using rHuEPO, it would be advisable to 
adjust the dose individually to the target Hb, ensure 
iron supply to the bone marrow (administering 
adjuvant iron, preferably IV), and provide adequate 
pharmacological thromboembolic prophylaxis. 
- Peri-operative or post-operative IV iron administration, 
with or without rHuEPO, is suggested for anaemic or 
iron-deficient patients undergoing major orthopaedic 
surgery when the time to surgery is short.
- An institutional algorithm for the detection, diagnosis 
and proper treatment of anaemia and haematinic 
deficiencies within a PBM programme may be a 
feasible, cost-effective strategy that is beneficial for 
both patients and healthcare systems.
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Spanish Best practice in perioperative anaemia 
optimisation panel (in alphabetical order):
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